What is the Difference Between Botulax and Botox | Composition, Efficacy, and Price

Both components are 900kDa botulinum toxin. Botox (USA) has high purity and low diffusion, with a unit price starting from approximately 3000 RMB; Botulax (South Korea) is highly cost-effective, with a price about 50% lower. The effects of both last for 3-6 months. Recommendation: Choose Botox for precise wrinkle removal, and choose Botulax for face and leg slimming or other large muscle shaping for better value.

Composition

The main component of both Botox and Botulax is 100 units of Type A botulinum toxin (150kDa active neurotoxin + 750kDa complex protein), both with a molecular weight of 900kDa. Botox uses the Hall strain, and each bottle of excipients contains 0.5mg of human serum albumin and 0.9mg of sodium chloride; Botulax uses the CBFC26 strain, and the excipient ratio is exactly the same as Botox. The difference between the two lies in the manufacturing technology: Botox uses patented vacuum drying, which maintains high protein integrity; Botulax uses freeze-drying.

Molecular Structure & Active Substances

This substance evolved from a single-chain polypeptide composed of 1296 amino acids. During bacterial growth, endogenous proteases cut this single chain to form a double-chain structure consisting of a 100kDa heavy chain and a 50kDa light chain. These two chains are connected by a disulfide bond, which is the primary physical connection for maintaining biological activity. The heavy chain part is mainly responsible for finding receptors on nerve endings, such as SV2 and gangliosides; the light chain is the biologically active part, containing a zinc-ion dependent peptidase that can cleave the SNAP-25 protein. Once this protein is destroyed, vesicles within the nerve cell cannot fuse with the cell membrane, resulting in the inability to release acetylcholine, so the muscle does not contract. This 150kDa neurotoxin molecule is the exact same active unit in both products. Surrounding the 150kDa toxin is a group of non-toxic accessory proteins, weighing a total of approximately 750kDa, which combine with the toxin to form a complex with a total molecular weight of 900kDa. These accessory proteins include:

• Non-toxic Non-hemagglutinin Protein (NTNH): With a molecular weight of about 138kDa, it tightly wraps the toxin molecule like a protective shell, preventing environmental factors from damaging the toxin.
• Hemagglutinin Protein (HA): Includes HA-70, HA-17, and HA-33. These proteins help the toxin cross the intestinal barrier in the natural state of Clostridium botulinum and primarily serve to stabilize the molecular structure in the pharmaceutical agent.
• Complex Ratio: Toxin molecules and NTNH proteins usually combine in a 1:1 ratio, while HA proteins attach to the outside in the form of polymers.

Botox uses the Hall strain (ATCC 3502), while Botulax uses the CBFC26 strain. For Botox, the purification process during production ensures a very constant ratio of the 900kDa complex, which makes the diffusion behavior of the medicinal solution highly predictable after injection. As a biosimilar, Botulax has a protein fingerprinting map highly close to Botox. In a liquid environment, when the pH value reaches above 7.0 (i.e., after entering human tissue fluid), this 900kDa complex dissociates rapidly, releasing pure 150kDa toxin molecules. In every 100 units (U) of the agent, the actual amount of active toxin protein contained is extremely small.

• Protein Content Data: 100 units of Botox contain approximately 0.73 nanograms (ng) of botulinum toxin protein.
• Excipient Ratio: Besides the toxin, each bottle also contains 0.5 mg of Human Serum Albumin and 0.9 mg of sodium chloride.
• Role of Albumin: Albumin acts as a carrier protein at this diluted concentration, primarily preventing trace amounts of toxin molecules from adsorbing onto the inner walls of the glass or the plastic tubing of the.

There are differences in the microscopic molecular arrangement between the patented vacuum drying technology used by Botox and the freeze-drying technology of Botulax. The vacuum drying process does not involve the freezing of water, which to some extent reduces protein folding errors or micro-aggregation that may occur during the freezing process. Botulax uses conventional freeze-drying, forming a white dry powder cake at the bottom of the. Research indicates that the potency deviation between batches of Botox is usually maintained within plus or minus 5%, a precision derived from the protection of the spatial conformation of the active molecules. At the molecular level, the blocking mechanism of the neuromuscular junction is completely equivalent for both.

• Binding Phase: The C-terminus of the heavy chain binds with gangliosides and SV2 proteins on the neuronal surface.
• Internalization Phase: Nerve cells wrap the toxin inside the cell through endocytosis.
• Translocation Phase: As the pH value within the endocytic vesicle decreases, the N-terminus of the heavy chain undergoes a conformational change, forming a channel for the light chain to pass through the vesicle membrane and enter the cytoplasm.
• Proteolysis Phase: The light chain that has entered the cytoplasm functions as a peptidase, specifically seeking out and cleaving SNAP-25.

Comparison of Excipient Components

Botox and Botulax show a high degree of convergence in the choice of excipients, a design intended to ensure that the biosimilar can simulate the behavior of the original drug to the greatest extent biologically. In every 100 units (U) of both agents, there are 0.5 mg of Human Serum Albumin and 0.9 mg of Sodium Chloride. Since the actual toxin protein weight in each 100U bottle of botulinum toxin is only about 0.73 ng, this amount is extremely tiny. If bottled directly, these tiny protein molecules would quickly adsorb onto the inner walls of the glass or the plastic tubing of the, causing the actual dose received by the patient to be much lower than the labeled units. 0.5 mg of albumin forms a high-concentration protein carrier environment in the solution, which preferentially occupies the adsorption sites on the wall, thereby keeping the toxin molecules in a free state. Additionally, albumin can buffer pH changes in the environment and protect the disulfide bonds on the toxin molecules from accidental oxidation, which is vital for maintaining the biological activity of the toxin.

During the reconstitution process, doctors usually add 0.9% physiological saline, and the 0.9 mg of sodium chloride in each bottle is meant to match this concentration. When the medicinal solution is injected into muscle tissue, an isotonic environment can reduce cell pressure in local tissues, thereby lowering the stinging sensation during injection. If the excipient ratio is improper, leading to osmotic pressure that is too high or too low, it may trigger a local inflammatory response or even accelerate the diffusion of the solution to surrounding non-target muscles. In laboratory stability tests, 0.9 mg of sodium chloride and 0.5 mg of albumin together build a micro-environment with a pH value between 6.0 and 7.0, which is the most stable range for the Type A botulinum toxin complex. Although the component lists are identical, the physical form of the two drugs differs due to the manufacturing process. Botox utilizes patented vacuum-drying technology, removing moisture without going through a freezing process. Under this process, excipients and toxins form an extremely transparent, almost invisible thin film at the bottom of the. In contrast, Botulax employs lyophilization technology (freeze-drying), where moisture sublimates after freezing at low temperatures. This process causes the excipients to form a white, loose powder Cake. Freeze-dried powder usually dissolves faster, while vacuum-dried films require more careful rotating and shaking to ensure complete dissolution.

The albumin used by Botox is a plasma extract screened according to standards, while Botulax uses plasma extract complying with Korean Pharmacopoeia standards. Although both undergo strict virus inactivation and purification processes (such as pasteurization and chromatography), protein ratios from different sources may produce different immune feedback in a very few highly sensitive individuals. Clinical data indicates that due to extremely high excipient purity, the local swelling rate caused by both is lower than 3%. This high purity also ensures that the product can maintain a shelf life of up to 36 months in a refrigerated environment of 2°C to 8°C. When the doctor adds the diluent at a ratio of 2.5 ml, the 0.5 mg of albumin in the will be evenly distributed. Because albumin has certain surface activity, if the physiological saline is pushed too quickly during reconstitution, bubbles may be generated. These bubbles increase the surface area of protein in contact with air, which can lead to denaturation and inactivation of the toxin protein. Since Botox is in film form, it has slightly higher sensitivity to this operation; the powder structure of Botulax alleviates the initial dissolution pressure to some extent. The excipients of both can provide good lubricity after reconstitution, allowing the solution to pass smoothly through 30G or 32G ultra-fine without crystal blockage.

Differences in Manufacturing Processes

The patented vacuum-drying technology developed by Allergan for Botox is its technical moat for maintaining its standard status in the botulinum toxin field for decades. In the production flow, the Botox medicinal solution undergoes moisture evaporation directly in a vacuum environment, a process that does not involve cooling the solution below the freezing point to form ice crystals. Since proteins are extremely sensitive to shear forces and phase changes, avoiding the freezing stage can effectively reduce the risk of dissociation between the active 150kDa neurotoxin and the surrounding 750kDa accessory protein complex. The finished product after vacuum drying forms a transparent dry film at the bottom of the with a thickness of only a few microns, making the look nearly empty to the naked eye. This process has extremely high equipment requirements and can strictly control the potency deviation of each batch within ±5%, ensuring extremely high predictability of drug performance across multiple injections. In the vacuum drying process, because liquid-solid phase changes are eliminated, the 3D structure of protein molecules is locked to the maximum extent, which allows Botox to maintain extremely high biological activity recovery after reconstitution. In contrast, Botulax adopts the lyophilization (freeze-drying) technology more common in the biopharmaceutical industry. In this process, the mixed solution containing Type A botulinum toxin, human serum albumin, and sodium chloride is first frozen to -40°C to -50°C to completely crystallize the moisture. Subsequently, in an ultra-low pressure environment, ice crystals are directly converted into water vapor through sublimation. Botulax after freeze-drying presents a white powder cake structure at the bottom of the, with a surface area much larger than the dry film of Botox. Although the physical pressure of ice crystals generated during the freeze-drying process might exert slight mechanical squeezing on the fragile accessory proteins, Hugel has successfully maintained the stability of Botulax’s active components at a level comparable to the original drug by precisely regulating the freezing curve of excipients. Data shows that Botulax under the freeze-drying process still maintains stability for a long time even at a room temperature of 25°C, providing a larger tolerance for cold chain transportation worldwide. The white powder cake generated by freeze-drying technology has an extremely high reconstitution speed. After adding physiological saline, the agent usually dissolves completely within 2 to 3 seconds, which slightly improves the convenience of clinical operations.

In terms of purification process

Botox uses the Hall strain, and its downstream process involves multiple ion-exchange chromatography and cryocentrifugation steps, aiming to thoroughly remove endotoxins, nucleic acids, and host cell proteins generated during the metabolism of Clostridium botulinum. Botulax, on the other hand, performs precise intervention on the ratio of metabolic products during the fermentation stage by optimizing the culture environment of the CBFC26 strain. Through high-resolution gel filtration chromatography, it can be seen that the 900kDa complex content in Botox is extremely high, and the proportion of fragmented proteins is extremely low. Botulax uses similar chromatography technology during the purification process, ensuring that the finished product does not contain any atypical impurities that might trigger an immune response. Laboratory data shows that the protein purity of Botulax reaches over 99.8%, making the probability of antibody production after multiple injections in the same data magnitude as Botox. The mass of active neurotoxin protein in every 100 units of purified Botox is approximately 0.73 ng. This extremely high purity is the physical foundation for reducing immune recognition and avoiding the production of neutralizing antibodies.

Water Content Control

Botox controls residual moisture below 3% through vacuum drying, while Botulax reaches the same drying standard in the freeze-drying process. Any minor excess in water content will cause hydrolysis of the disulfide bonds in botulinum toxin, leading to loss of efficacy. At the end of the production line, the filling environment for Botox is maintained in a high-specification dust-free workshop, coupled with a precise nitrogen-filling process to exclude oxygen interference. Botulax utilizes an automated visual inspection system during the sub-packaging stage to scan each powder cake at the bottom of the, discarding any structural flaws caused by uneven freezing speeds. Differences in manufacturing processes lead to different operation feels during reconstitution. The vacuum-dried film requires the solution to be slowly pushed in along the wall and rotated gently, while the powder-form freeze-dried product has a higher tolerance for pushing speed.

Physical Form Differences

Since Botulax is a powder for reconstitution, the initial distribution of molecules in the solution is more uniform. In laboratory tests of gel diffusion models, the diffusion circle diameter of Botox is usually 10% to 15% smaller than common botulinum toxin products of the same concentration, which is inseparable from the protection of the complex protein structure by its vacuum drying process. As a biosimilar, Botulax’s process logic is to simulate this low-diffusion characteristic of Botox as much as possible, making the behavior logic of the finished product in tissue approach the original standard by fine-tuning the freeze-sublimation rate. Temperature fluctuations during the production process are limited to within ±0.5°C. Any out-of-spec temperature change will directly lead to batch scrapping. This rigorous process monitoring mechanism is a shared guarantee for both to maintain high safety.

Packaging and Sealing Technology

Botox adopts a special cap system to maintain a vacuum negative pressure environment inside the. this negative pressure state is also an important sign for doctors during reconstitution to judge whether the drug has leaked or failed. When the pierces the stopper, the negative pressure will automatically suck in the physiological saline. Botulax also uses similar negative pressure encapsulation technology to ensure that external air cannot enter the to destroy the dry state during transportation.

Efficacy

Clinical multicenter randomized double-blind trial data shows that Botulax and Botox have 1:1 dose equivalence in improving moderate to severe glabellar lines. In observations of over 300 subjects, the responder rate reached over 90% for both 4 weeks after injection, with no statistically significant difference. The diffusion diameter of Botox is usually stable at 0.5-1.0cm, while the muscle relaxation potency and onset node of Botulax are basically synchronized with those of Botox at the same concentration, usually starting to show effects within 48-72 hours and reaching peak efficacy on the 14th day.

Equivalence Comparison

Both Botox (OnabotulinumtoxinA) and Botulax (LetibotulinumtoxinA) are 900kDa Type A botulinum toxin complexes in molecular structure, containing a 150kDa core active neurotoxin and related non-toxin hemagglutinin proteins. According to multiple in vitro potency experiment data, both products show extremely high synchronization in the efficiency of cleaving the synapse-related protein SNAP-25, which is the physical basis for blocking the release of acetylcholine from nerve endings and thereby causing muscle relaxation. In a Phase III clinical trial for moderate to severe glabellar lines, subjects were randomly assigned to receive 20 Units of Botox or Botulax. results showed that the responder rates (Investigator’s Global Assessment score of 0 or 1) on day 30 reached 93.89% and 94.03% respectively. the 95% confidence interval of the difference fell completely within the preset equivalence margin (-15% to 15%), confirming the bioequivalence of the two at a 1:1 dosage ratio from a statistical perspective.

Long-term follow-up data regarding the efficacy decay cycle indicates that the clinical performance of Botulax at week 8 and week 12 almost overlaps with Botox. At the 12-week follow-up point, the maintenance rate for glabellar line improvement for both remains between 78% and 80%, with no premature efficacy fading observed due to different product sources. Through electromyography (EMG) monitoring, it was found that 14 days after injection, the intensity of electrical signal blocking produced by both toxins on target muscles reached its peak, with the average decrease in muscle contraction strength exceeding 85%. In terms of excipient composition, both use sodium chloride and Human Serum Albumin as stabilizers, which helps maintain the spatial conformation of toxin molecules during vacuum drying or lyophilization. Due to the high overlap in component ratios, Botulax is widely regarded as a biosimilar of Botox. in non-inferiority studies in multiple regions such as Europe and North America, its clinical feedback shows extremely high predictability, allowing users switching from Botox to Botulax to not need to adjust existing injection sites or dosage units.

In a safety pooled analysis covering over 500 subjects, there was no statistically significant difference in the incidence of treatment-emergent adverse events (TEAEs) between the Botox and Botulax groups. The most common reactions included temporary redness and swelling at the injection site, mild headache, or a fleeting sensation of heavy eyelids, which usually resolved spontaneously within 72 hours. Regarding monitoring of drug diffusion range, by measuring the degree of muscle paralysis in the area 0.5cm to 1.5cm around the injection point, Botulax demonstrated precision highly close to Botox, with no risks of non-target muscle weakness such as Ptosis or dysphagia due to an excessively large diffusion radius. In a laboratory environment, by re-calibrating the LD50 (Median Lethal Dose) unit potency of both agents, it was confirmed that the biological activity contained in each unit of Botulax has a highly consistent potency strength with standard units of Botox.

Time for Effects to Appear

In the initial 24 to 48 hours after injection, botulinum toxin molecules enter the interior of neurons through endocytosis and begin cleaving the SNAP-25 protein in the cytoplasm. Although users usually cannot observe the disappearance of wrinkles with the naked eye at this very early stage, laboratory data indicates that the amount of acetylcholine released at the neuromuscular junction has already started a detectable decline. In clinical observations of 300 subjects, approximately 15% to 20% of users will feel a slight tightness in the injection area around the 2nd day, a physical sensation that is usually the initial signal that the drug is beginning to take effect.

From the 3rd to 5th day after injection, the efficacy enters a rapid climbing period. In this stage, the signals output from motor nerve endings are no longer sufficient to support strong muscle contraction. users can feel that the depth of wrinkle creases is significantly shallower when making expressions. For shallow dynamic wrinkles like glabellar lines and crow’s feet, the improvement at this time can usually reach more than 50% of the target goal. Research points out that due to its complex protein encapsulation process, the release of active ingredients of Botox in local tissues is very stable, and the performance of Botulax at the same concentration also shows extremely high stability. In multicenter studies targeting North American and Asian populations, under standardized operations with 100U of agent diluted with 2.5ml of physiological saline, the clinical score (IGA score) improvement of both toxins on the 5th day basically overlapped. As time progresses to the 7th to 14th day, the efficacy will reach its highest peak level. The 14th day is the clinically recognized “gold standard” observation point and an important moment for doctors to evaluate if a touch-up is needed. At this time, the electrical signal activity of the target muscle is blocked to the lowest point. electromyography (EMG) tests show that the muscle action potential amplitude will usually decrease by more than 90%. For users with Masseter hypertrophy, although the nerve block is completed within two weeks, the visual reduction in muscle volume requires more time. This is because the improvement of muscle hypertrophy depends on the “disuse atrophy” process, where muscles gradually become smaller because they do not contract for a long time. According to 3D scanning data, visual feedback of masseter reduction usually begins to appear around the 4th week and reaches the peak of volume reduction around the 8th week, with an average reduction of 25% to 30%.

• Initial Infiltration Phase (Day 1-2): Toxin molecules penetrate the cell membrane. Efficacy at this time is in a “silent period,” unaffected by external massage or hot compresses (though clinical advice is against massage to prevent diffusion).
• Onset Turning Phase (Day 3-4): Most users start to notice the disappearance of dynamic creases when washing their face or applying makeup.
• Stable Maturation Phase (Day 7-10): Muscle movement restriction becomes natural, and the initial stiffness is no longer felt.
• Efficacy Peak Phase (Day 14): SNAP-25 protein is cleaved to the maximum extent, and the effect at this time determines the future maintenance duration.

Around the 3rd month after injection, nerve endings begin to attempt to re-establish connections with muscles through “Axonal Sprouting.” In this stage, users will feel that muscle strength is slowly recovering, and wrinkles will appear slightly when applying extreme force. By the 4th or 5th month, these new nerve endings will gradually mature and restore most of their chemical transmission functions, at which time the next preventive injection is needed. Data proves that regular long-term injections (e.g., once every 4 to 6 months) can lead to adaptive thinning of the muscle, which may cause the onset time of subsequent effects to be slightly earlier and the maintenance time to potentially extend from the initial 4 months to over 6 months.

Efficacy for Different Symptoms

Dynamic Facial Wrinkles

In the treatment of dynamic facial wrinkles, especially for moderate to severe glabellar lines, multiple multicenter studies have quantitatively evaluated an injection dose of 20 Units. Data shows that the responder rate for Botox on day 30 after injection usually stays around 93.8%, while Botulax’s performance at the same dose is 94.1%. there is no statistical superiority or inferiority between the two in terms of efficacy. By monitoring the facial expression muscle potential of 400 subjects, it was found that at maximum frowning, both toxins could reduce the muscle action potential amplitude by more than 85%, thereby significantly smoothing the creases on the skin surface.

Clinical experiments show that at a 1:1 dose ratio, the improvement in IGA (Investigator Global Assessment) for glabellar lines with Botulax and Botox reached a high degree of overlap at 4 weeks.

Masseter Hypertrophy

In clinical observations of 25 to 30 units injected into each side of the masseter muscle, the reduction ratio of muscle thickness for both Botox and Botulax fell within the range of 22% to 28% at week 8. Although the blocking of nerve signals is completed within 14 days after injection, physical atrophy of muscle fibers requires a longer time cycle. Precise measurement of muscle volume through Magnetic Resonance Imaging (MRI) found that the volume changes in the mandibular angle area for both products at week 12 were almost completely equivalent, with volume reductions between 1.5 to 2.2 cubic centimeters.

In a 3D scan follow-up of 150 patients with masseter hypertrophy, visual scores for contour reduction in the Botox and Botulax groups at the 3rd month both reached over 3.5 points (out of 5).

Hyperhidrosis

In the treatment of axillary hyperhidrosis, a multi-point injection plan of 50 units in each axilla is usually adopted. According to quantitative results of Minor’s Test (iodine-starch test), one week after injection, the reduction in sweating area in the Botox group reached 82%, while the reduction rate in the Botulax group was 81.5%. Gravimetric measurements showed that the weight of sweat produced per minute dropped from an average of 150 mg before treatment to below 20 mg. This ability to regulate the autonomic nervous system is equally efficient in both products, with maintenance time usually covering the entire summer (about 6 to 7 months).

Axillary hyperhidrosis subjects had their HDSS (Hyperhidrosis Disease Severity Scale) scores drop from an average of 3.2 to 1.1 after 100U treatment, with the difference in efficacy between the two agents being less than 1%.

Fine Periorbital Lines

Because Botox adopts unique 900kDa protein complex encapsulation technology, the molecular stability after dilution gives it excellent positioning precision in the thin tissues around the eyes. Experimental data shows that on the 14th day after injecting 12 units on one side, both static and dynamic crow’s feet depth decreased by more than 70%. Botulax’s performance in this area also meets clinical expectations. although its diffusion radius showed slight fluctuations in some high-dilution experiments, under standard concentration (1.25ml diluent/100U), its improvement effect on the lateral eye contour maintained high similarity with Botox, and no non-target muscle paralysis due to drug diffusion was observed.

In injections into fine periorbital areas, the diffusion radius deviation between Botox and Botulax is usually controlled within 0.2 cm, and efficacy showed no significant difference during the 3-month follow-up period.

In large-area body shaping applications, such as slimming calves (gastrocnemius) and shoulders (trapezius), the required dose usually reaches 100 to 200 units. In clinical interventions for the gastrocnemius, starting from the 4th week after injection, the muscle protrusion when subjects stand on their toes is significantly softened. Data indicates that the systemic tolerance of Botulax at high doses is consistent with Botox, and increased doses did not lead to higher antibody production rates. In quantitative measurements at week 8, the circumference at the thickest part of the calf was reduced by an average of 1.5 to 2.5 cm.

A 200U injection study for the trapezius showed that visual improvement of shoulder contours with Botox and Botulax both reached 88% patient satisfaction at 12 weeks.

In skin-surface injection plans (Micro-botox) to improve enlarged pores and sebum secretion, both Botox and Botulax effectively enhance overall skin texture by acting on the arrector pili muscles and sebaceous glands. After multi-point superficial injections in the mid-face, subjects’ Sebum Excretion Rate (SER) decreased by 30% to 45% by the 2nd week. This efficacy against skin appendages once again proves the high degree of overlap in biological effects between the two products. Whether for structural relaxation of deep muscles or texture regulation of superficial skin, the success rate of both products demonstrates extremely high predictability. Since the molecular weight of their core active ingredient is 150kDa, their similarity in receptor binding efficiency and biodegradation pathways ensures a seamless switch for users between different treatment projects.

Price

The terminal purchase price for the 100U specification of Botox in the international market is approximately 300 to 600 USD, with the average cost per unit of treatment falling between 10 to 20 USD. In contrast, the purchase cost of 100U of Botulax is only 100 to 250 USD, with the cost per unit usually between 5 to 10 USD. This 2 to 3 times price difference primarily stems from brand premium, R&D cost amortization, and global cold chain logistics requirements. In markets like Latin America and Southeast Asia, Botulax has rapidly gained a large number of young groups pursuing high cost-effectiveness due to its price advantage of 40% to 60% lower than Botox.

Market Average Cost Comparison

The clinic purchase price for the 100U specification of Botox in the international market is stable between 520 USD to 620 USD, and the per-unit fee paid by end users is usually 15 USD to 25 USD. The purchase cost for 100U of Botulax is significantly lower, with overseas distributor quotes mostly between 120 USD to 180 USD, and the retail price per unit borne by consumers is about 7 USD to 12 USD. This 2.5 to 3.5 times price difference reflects differences in production processes, R&D amortization, and global logistics costs. In medical aesthetic institutions in Bangkok or London, the average total expenditure for full-face wrinkle removal using Botulax is about 45% to 60% lower than using Botox. Botox, produced by Allergan in the USA, uses unique air-mixing technology for vacuum drying. its wholesale price is strictly controlled in North America, with the wholesale price for a 50U package being about 300 USD and 100U about 570 USD. Clinics usually add a markup of 100% to 200% on top of the purchase price to cover high operating costs, practitioner insurance, and professional training fees. This means if a user has forehead and crow’s feet injections at a clinic in Los Angeles, using a total of 40 units, the final bill will often reach 800 USD to 1,000 USD. In comparison, Botulax produced by Hugel in South Korea uses its lower production costs and shorter supply chain paths when entering international markets like Brazil or Southeast Asia, keeping the export price for a 100U bottle below 150 USD.

Pricing Models

Most North American clinics charge per unit, which requires users to have a clear understanding of the dose used. For example, masseter hypertrophy (face slimming) usually requires a total of 50 to 60 units for both sides. If choosing Botox, the single treatment cost is around 750 USD to 1,200 USD; switching to Botulax, the expenditure for the same dose will drop to 350 USD to 600 USD. Another group of clinics charges a fixed fee per area, a model more common in Europe and Australia. The fixed fee per area for forehead lines is about 300 USD under the Botox plan, while the Botulax plan may only require 150 USD to 180 USD. This difference is particularly pronounced in parts requiring large-dose injections, such as calf muscle reduction (usually needing 100-200 units), where the gap in total expenditure can reach over 1,500 USD.

Labor Costs and Medical Level

In London or New York, with a standard procedure performed by a professionally trained dermatologist, the injection fee per unit will increase by an extra 5 to 10 USD as a technical service fee. In contrast, at medical aesthetic clinics (Med-spas) staffed with Registered Nurses (RN) or Physician Assistants (PA), the operation fee will be much lower. Because of its lower purchase price, Botulax is usually the main product promoted by these medium-sized aesthetic institutions to lower the threshold for customer acquisition. Data shows that among users choosing Botulax, about 65% enter because of its lower cost for a single attempt, while Botox users show higher brand loyalty, with 70% being repeat customers with over 3 years of injection experience.

Long-term Maintenance Costs

The efficacy of botulinum toxin usually lasts for 3 to 5 months, meaning users need about 3 supplemental injections per year. Taking an active user consuming an average of 120 units per year (including wrinkle removal and face slimming) as an example, the annual maintenance cost for Botox is about 1,800 USD to 2,400 USD. If switching to the Botulax plan, the total annual expenditure can be controlled between 800 USD to 1,200 USD. The over 1,000 USD saved in between is enough to pay for extra skin care or laser treatment fees.

Long-term Maintenance Budget

Botulinum toxin is not a one-time purchase. its metabolic cycle in the human body is usually 3 to 5 months, meaning users seeking continuous effects need regular injections 3 times a year. For a standard middle-aged anti-aging user, if they inject 3 times a year, treating the forehead (20U), glabella (25U), and crow’s feet (20U) each time, the total annual consumption is 195 units. In high-end clinics in North America or Europe, the annual expenditure for using Botox will reach 2,900 USD to 4,800 USD. If choosing the Botulax plan, because its price per unit stays at 7 USD to 12 USD, the same annual dose only requires an expenditure of 1,300 USD to 2,300 USD. This annual difference of 1,600 USD to 2,500 USD will accumulate to a significant figure close to 10,000 USD over a 5-year maintenance cycle, enough to pay for several full-face picosecond laser or entry-level Thermage treatments.

Shaping

For shaping needs for large muscle groups, such as relieving trapezius hypertrophy (shoulder slimming) or gastrocnemius hypertrophy (calf slimming), each injection dose is usually as high as 100 to 200 units. At private aesthetic institutions in London, a single 200U Botox calf slimming treatment often breaks 3,000 USD, and the total expenditure for two injections per year is as high as 6,000 USD. In contrast, the performance of Botulax in such large-dose needs is more in line with the expectations of users with budget constraints, as a single treatment can be controlled at around 1,400 USD. Statistics show that about 78% of large-dose injection users will switch to Botulax or similar cost-effective plans after continuous use for 2 years to reduce the economic burden brought by long-term maintenance.

• Tiered Discount Strategy: Many international clinics provide “Unit Package” services for long-term users. purchasing a 500U Botox pre-stored package may lower the unit price to 12 USD, bringing the annual wrinkle removal cost down to around 2,300 USD. Botulax has larger pre-stored discounts, and in the large-package purchase model, the unit fee can be compressed to below 6 USD.
• Efficacy Decay Cost: As the number of injections increases, a tiny fraction of users will produce antibodies, causing the efficacy maintenance time to shorten from 5 months to 2.5 months. if this happens, the injection frequency needs to increase to 4-5 times per year. under this extreme assumption, the annual maintenance cost for Botox would surge to over 6,000 USD, while for Botulax users, although expenditure would also double, the annual total can still stay within a controllable range of 3,000 USD.
• Physician Technical Surcharge: Although there is a price difference for the agent, the technical fee for professional injection is basically consistent between different brands. in New York, regardless of the agent used, the physician operation fee is usually fixed at 150 to 300 USD per time. for the low-unit-price Botulax, the operation fee accounts for a higher percentage of total expenditure (about 30%), while Botox users pay more for the brand premium itself.
• Regional Price Fluctuations: In tax-free ports or specific medical aesthetic travel destinations (like Bangkok), the price for a 100U Botulax package is year-round around 200 USD (including operation fee). international users frequently visiting such areas can reduce their annual maintenance budget to 600 USD. In contrast, the global price system for Botox is very firm, and promotions lower than 30% of the average market price are extremely rare.

Touch-up Fees

Around 14 days after the initial injection, if there are still dynamic wrinkles in the area, clinics usually need to add 5 to 10 units. Some high-end clinics using Botox will include this fee in the initial high unit price, with no extra charge. However, affordable clinics featuring Botulax often adopt a transparent “pay by volume” model, where touch-up fees are calculated based on the actual units consumed. Although this increases the trivial expenses per visit, from an annual audit perspective, the pay-by-volume model still has an advantage of over 35% in total expenditure.

Different Age Groups

Preventive anti-aging users (Baby Botox) aged 25 to 30 usually only need about 20U per time, and with slow metabolism, they only need injections 2 times a year. The annual expenditure for this group using Botox is about 600 USD, and the difference from 300 USD for Botulax is not significant, so more young users tend to start trying with Botox. However, users over 45 years old often need 3-4 injections per year due to deeper wrinkles and stronger muscle strength, with single doses exceeding 50U. At this time, the price leverage effect between the two brands rapidly amplifies. The annual price difference of 3,000 USD is often the decisive reason for users in this age group to switch to Botulax.

Pricing in Different Regions

North American Market

In the North American market, Botox maintains extremely high price stability, with the wholesale unit price for 100U in the US long staying between 570 USD to 630 USD. Limited by the strict entry system of the , Botulax has not yet obtained full prescription permission in the US, but in regions like Canada, its purchase price through parallel import or specific compliant channels is only 180 USD to 240 USD. This regional entry barrier makes the per-unit charge for Botox at clinics in New York or Toronto usually no lower than 15 USD, and in some high-end dermatology clinics, this figure even soars to 25 USD.

In medical aesthetic centers in Manhattan, New York, a standard wrinkle removal treatment for 3 areas (forehead, glabella, crow’s feet) using Botox has an average bill of 800 USD to 1,200 USD, while the expenditure for the same dose in regions where Korean drugs are legally allowed can be directly reduced to around 400 USD.

et

Pricing logic in the et is significantly affected by Value Added Tax (VAT) and the medicine regulatory agencies of member states (such as the UK MHRA). In London, the retail price per unit of Botox is about 12 to 18 GBP (about 15 to 23 USD), while Botulax from Korea, after obtaining CE certification to enter the EU market, has rapidly penetrated mid-tier aesthetic institutions with its lower wholesale cost. In Berlin or Paris, the purchase cost for a 100U bottle of Botulax is about 140 to 170 EUR, which allows local clinics to promote it to users at an extremely low unit price of around 9 EUR. Statistics show that in mainland Europe, about 60% of users choosing Botulax are first-time consumers aged 25 to 35 who are extremely sensitive to price fluctuations.

Aesthetic chains in the UK usually launch “three-area packages.” the package price using Botox is mostly 250 to 350 GBP, while the package price for similar products like Botulax only requires 150 to 190 GBP, and includes one free touch-up service.

Southeast Asia

In Bangkok or Ho Chi Minh City, due to short logistics paths and low import duties, the 100U Botulax clinic purchase price is year-round maintained at 110 to 150 USD. In mall clinics in Bangkok, the total expenditure for a full-face 50U Botulax injection is often less than 200 USD. In contrast, the market premium for Botox still exists in these regions, with the purchase price for 100U still over 450 USD. This makes Botulax one of the most cost-effective projects in the Southeast Asian medical tourism list, with its consumption market share in Thailand and elsewhere exceeding 40%.

In medical aesthetic clinics in Thailand, for a specialized treatment for masseter hypertrophy, the flat rate for Botulax 50U is usually 5,000 to 7,000 THB (about 140 to 200 USD), while Botox for the same dose requires over 12,000 THB.

Latin American Market

In São Paulo, Brazil, Botox is viewed as a “luxury medical supply,” with unit charges as high as 40 to 60 BRL (about 8 to 12 USD, but this is quite high relative to local income levels). Botulax, through cooperation with local large medical distributors, has successfully pushed the 100U landed price down to around 130 USD. In Mexico City, many clinics attract users needing calf or shoulder muscle reduction by providing large-package (200U) injection plans for Botulax, with the total expenditure for such projects saving about 55% in cash compared to using Botox.

Medical aesthetic market research reports in Brazil indicate that in the past 24 months, due to inflation, the proportion of users switching to Botulax increased by 22%, as its annual maintenance fee can drop from 4,000 BRL to around 1,800 BRL.

Temperature Control Costs in Different Regions

Botox is produced in Ireland. when shipped to the Middle East (such as Dubai or Abu Dhabi), it must use cold chain containers with real-time temperature monitoring. this high-end logistics costs about 25 USD per bottle when shared. When Botulax enters these markets, it often keeps the landed price per bottle at one-third of Botox through more flexible distribution strategies and relatively lower brand maintenance fees. In top clinics in Dubai, although practitioners are more inclined to recommend Botox to match brand positioning, in many ordinary community clinics, Botulax holds more than half of the market share with a price advantage of only 25 to 35 AED (about 7 to 10 USD) per unit.

• North America (inc. US/Canada): Botox dominates, unit price $15-$25. Botulax is only available in specific areas due to compliance limits, with unit price around $8-$12.
• Europe (inc. UK/Germany/France): Botox unit price €15-€20. Botulax is widely distributed with CE certification, unit price €8-€11.
• Asia-Pacific (inc. Thailand/Singapore/Australia): Botulax is extremely price-competitive, unit price $6-$10. Botox remains at $12-$18 with very few promotions.
• Middle East & Latin America: Botulax attracts clinics with high profit margins, with terminal prices usually 40% to 50% of Botox.